Table of contents

April 2017 - Volume 2 - 1


A

  1. Ansaloni, Silvia

    1. Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study
      Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti
  2. Aprile, Giuseppe

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
  3. Arnoldi, Ermenegildo

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
  4. Aschele, Carlo

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
  5. Azambuja, Evandro de

    1. Male breast cancer: finding the way in this uncommon path
      Christian Maurer, Samuel Martel, Evandro de Azambuja

B

  1. Baba, Hideo

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
  2. Banerjee, Susana

    1. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
      Saoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana Banerjee
  3. Barrueco, José

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
  4. Beretta, Giordano D

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
  5. Bhattacharjee, Atanu

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
  6. Boku, Narikazu

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka

C

  1. Caglevic, Christian

    1. Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
      Satheesh Thungappa, Jose Ferri, Christian Caglevic, Francesco Passiglia, Luis Raez, Christian Rolfo
  2. Carnaghi, Carlo

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
  3. Cervantes, Andrés

    1. In the literature: February 2017
      Andrés Cervantes, María José Terol
  4. Chan, Anthony TC

    1. Biologics and biosimilars: what, why and how?
      Juliana CN Chan, Anthony TC Chan
  5. Chan, Juliana CN

    1. Biologics and biosimilars: what, why and how?
      Juliana CN Chan, Anthony TC Chan
  6. Chandrasekharan, Arun

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
  7. Cheng, Ann-Lii

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
  8. Chouaki, Nadia

    1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
      Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia Novello
  9. Choughule, Anuradha Bharat

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
  10. Cosimelli, Maurizio

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta

D

  1. Degli Esposti, Claudia

    1. Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study
      Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti
  2. Della-Pepa, Chiara

    1. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
      Saoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana Banerjee
  3. Dolly, Saoirse O

    1. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
      Saoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana Banerjee

E

  1. Egawa, Shinichi

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka

F

  1. Ferri, Jose

    1. Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
      Satheesh Thungappa, Jose Ferri, Christian Caglevic, Francesco Passiglia, Luis Raez, Christian Rolfo
  2. Funakoshi, Akihiro

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
  3. Furuse, Junji

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka

G

  1. Gann, Claudia-Nanette

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
  2. Garrido, Pilar

    1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
      Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia Novello
  3. Gaschler-Markefski, Birgit

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
  4. Giraud, Philippe

    1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
      Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia Novello
  5. Goel, Alok

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
  6. Gottfried, Maya

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
  7. Goud, Supriya

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash

H

  1. Hagiwara, Yasuhiro

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
  2. Hanna, Nasser H

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
  3. Hashida, Hiroki

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
  4. Hashimoto, Kazuki

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
  5. Hatachi, Yukimasa

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
  6. Hatori, Takashi

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
  7. Hattori, Takayuki

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
  8. Hayashi, Hidetoshi

    1. Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab
      Ryoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko Nakagawa
  9. Hazell, Steve

    1. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
      Saoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana Banerjee
  10. Heymach, John V

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
  11. Hohokabe, Eri

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo

I

  1. Ichikawa, Chihiro

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
  2. Imagumbai, Toshiyuki

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
  3. Imai, Yukihiro

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
  4. Ioka, Tatsuya

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
  5. Iwamoto, Shigeyoshi

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara

J

  1. Janu, Amit

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
  2. Joshi, Amit

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash

K

  1. Kaihara, Satoshi

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
  2. Kaiser, Rolf

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
  3. Karpe, Ashay

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
  4. Kato, Hironori

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
  5. Kato, Ryoji

    1. Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab
      Ryoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko Nakagawa
  6. Kato, Takeshi

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
  7. Kaye, Stanley B

    1. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
      Saoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana Banerjee
  8. Khakoo, Shelize

    1. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
      Saoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana Banerjee
  9. Kihara, Kiyohiro

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
  10. Kikawa, Yuichiro

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
  11. Kobayashi, Hiroyuki

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
  12. Kokubo, Masaki

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
  13. Komatsu, Yoshito

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
  14. Kondo, Masato

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
  15. Kosaka, Yasuhiro

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
  16. Kotaka, Masahito

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
  17. Kotake, Takeshi

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
  18. Kumar, Rajiv

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash

L

  1. Lelli, Giorgio

    1. Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study
      Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti

M

  1. Mahajan, Abhishek

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
  2. Maiello, Evaristo

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
  3. Martel, Samuel

    1. Male breast cancer: finding the way in this uncommon path
      Christian Maurer, Samuel Martel, Evandro de Azambuja
  4. Martoni, Andrea A

    1. Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study
      Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti
  5. Matsumoto, Hiroshi

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
  6. Maurer, Christian

    1. Male breast cancer: finding the way in this uncommon path
      Christian Maurer, Samuel Martel, Evandro de Azambuja
  7. Mellemgaard, Anders

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
  8. Melotti, Barbara

    1. Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study
      Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti
  9. Migali, Cristina

    1. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
      Saoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana Banerjee
  10. Miki, Akira

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
  11. Mishima, Hideyuki

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
  12. Mizumoto, Kazuhiro

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
  13. More, Sucheta

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
  14. Morita, Satoshi

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
  15. Muro, Kei

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
  16. Murotani, Kenta

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
  17. Mutri, Vita

    1. Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study
      Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti

N

  1. Nakagawa, Kazuhiko

    1. Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab
      Ryoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko Nakagawa
  2. Nakamura, Masato

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
  3. Narukami, Ryo

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
  4. Normanno, Nicola

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
  5. Noronha, Vanita

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
  6. Novello, Silvia

    1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
      Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia Novello
    2. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser

O

  1. Ogura, Kengo

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
  2. Ohashi, Yasuo

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
  3. Ohkawa, Shinichi

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
  4. Okita, Yoshihiro

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
  5. Okusaka, Takuji

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka

P

  1. Pande, Nikhil

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
  2. Pannuti, Franco

    1. Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study
      Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti
  3. Passiglia, Francesco

    1. Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
      Satheesh Thungappa, Jose Ferri, Christian Caglevic, Francesco Passiglia, Luis Raez, Christian Rolfo
  4. Patil, Vijay Maruti

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
  5. Piva, Erico

    1. Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study
      Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti
  6. Prabhash, Kumar

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
  7. Purandare, Nilendu

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash

R

  1. Raez, Luis

    1. Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
      Satheesh Thungappa, Jose Ferri, Christian Caglevic, Francesco Passiglia, Luis Raez, Christian Rolfo
  2. Ramaswamy, Anant

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
  3. Reck, Martin

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
  4. Ricardi, Umberto

    1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
      Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia Novello
  5. Rolfo, Christian

    1. Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
      Satheesh Thungappa, Jose Ferri, Christian Caglevic, Francesco Passiglia, Luis Raez, Christian Rolfo

S

  1. Sakata, Yuh

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
  2. Salvatore, Lisa

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
  3. Sasaki, Yasutsuna

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
  4. Satake, Hironaga

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
  5. Sato, Atsushi

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
  6. Satoh, Taroh

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
  7. Sciallero, Stefania

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
  8. Serke, Monika

    1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
      Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia Novello
  9. Shimada, Ken

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
  10. Shimada, Yasuhiro

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
  11. Sikken, Patricia

    1. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
      Birgit Gaschler-Markefski, Patricia Sikken, John V Heymach, Maya Gottfried, Anders Mellemgaard, Silvia Novello, Claudia-Nanette Gann, José Barrueco, Martin Reck, Nasser H Hanna, Rolf Kaiser
  12. Sobrero, Alberto

    1. The hard road to ranking the clinical benefit of antineoplastic agents: ESMO Award 2016 presentation
      Alberto Sobrero
  13. Soldatenkova, Victoria

    1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
      Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia Novello
  14. Strocchi, Elena

    1. Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study
      Andrea A Martoni, Barbara Melotti, Claudia Degli Esposti, Vita Mutri, Giorgio Lelli, Silvia Ansaloni, Erico Piva, Elena Strocchi, Franco Pannuti
  15. Sugihara, Kenichi

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara

T

  1. Takahari, Daisuke

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
  2. Takahashi, Keiichi

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
  3. Takebe, Sayaka

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
  4. Takeda, Masayuki

    1. Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab
      Ryoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko Nakagawa
  5. Talreja, Vikas

    1. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
      Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
  6. Tanaka, Kaoru

    1. Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab
      Ryoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko Nakagawa
  7. Tanaka, Masao

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
  8. Tanizaki, Junko

    1. Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab
      Ryoji Kato, Hidetoshi Hayashi, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuhiko Nakagawa
  9. Terol, María José

    1. In the literature: February 2017
      Andrés Cervantes, María José Terol
  10. Thungappa, Satheesh

    1. Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
      Satheesh Thungappa, Jose Ferri, Christian Caglevic, Francesco Passiglia, Luis Raez, Christian Rolfo
  11. Tsuji, Akihito

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
  12. Tunariu, Nina

    1. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
      Saoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, Susana Banerjee

U

  1. Ueki, Kazuhiro

    1. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey
      Yuichiro Kikawa, Yasuhiro Kosaka, Kazuki Hashimoto, Eri Hohokabe, Sayaka Takebe, Ryo Narukami, Takayuki Hattori, Kazuhiro Ueki, Kengo Ogura, Toshiyuki Imagumbai, Hironori Kato, Masaki Kokubo
  2. Ueno, Hideki

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka

V

  1. Vallejo, Carmen

    1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
      Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia Novello
  2. Valvo, Francesca

    1. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
      Lisa Salvatore, Giuseppe Aprile, Ermenegildo Arnoldi, Carlo Aschele, Carlo Carnaghi, Maurizio Cosimelli, Evaristo Maiello, Nicola Normanno, Stefania Sciallero, Francesca Valvo, Giordano D Beretta
  3. Visseren-Grul, Carla

    1. Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
      Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova, Silvia Novello

W

  1. Watanabe, Masahiko

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara

Y

  1. Yamada, Yasuhide

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
  2. Yamaguchi, Taketo

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
  3. Yamao, Kenji

    1. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
      Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka
  4. Yasui, Hisateru

    1. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
      Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
  5. Yoshida, Kazuhiro

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara
  6. Yoshida, Motoki

    1. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
      Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara